• Robust commercial momentum with case volumes more than doubling from Q4 2025
• 41 commercial patients implanted with the WiSE System in Q1 2026, bringing total implants to 71
• Preliminary unaudited revenue expected in the range of US$2.25M to US$2.36M for Q1 2026

EBR Systems, Inc. reported robust commercial momentum in Q1 2026, with case volumes more than doubling from Q4 2025. The company successfully implanted the WiSE System in 41 commercial patients during the quarter, bringing the total implants across the pilot phase and Limited Market Release to 71. EBR expects to report revenue in the range of US$2.25M to US$2.36M for Q1 2026, based on preliminary unaudited quarter-end results. The Limited Market Release continued to advance, with an additional 16 purchase agreements signed and 22 more physicians trained to support the adoption of the WiSE System. EBR also made progress on its clinical initiatives, with further enrollment in the WiSE-UP post-approval study and the TLC-AU feasibility study. The company remains focused on disciplined execution, physician training, site activation, and building the clinical and commercial foundation for broader adoption of the WiSE System.

EBR expects to report revenue in the range of US$2.25M to US$2.36M for Q1 2026, based on preliminary unaudited quarter-end results.